Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Kenneth C. Rupert, James R. Henry, John H. Dodd, Scott A. Wadsworth, Druie E. Cavender, Gilbert C. Olini, Bohumila Fahmy, John J. Siekierka

Research output: Contribution to journalArticle

198 Scopus citations


The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

Original languageEnglish
Pages (from-to)347-350
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Issue number3
StatePublished - 1 Feb 2003


Cite this

Rupert, K. C., Henry, J. R., Dodd, J. H., Wadsworth, S. A., Cavender, D. E., Olini, G. C., Fahmy, B., & Siekierka, J. J. (2003). Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorganic and Medicinal Chemistry Letters, 13(3), 347-350.